Oral GLP-1 Orforglipron (Foundayo) Achieves Weight Loss for Women of All Ages

A new analysis found that the diabetes medication orforglipron (Foundayo), an oral GLP-1, helped women lose weight regardless of their menopausal status. Healthline/Photo by Eli Lilly A new analysis of previous studies found that orforglipron promoted weight loss in women regardless of their menopausal status. This is important since the decline in estrogen after menopause can make weight loss more difficult. Menopausal women also tend to gain weight around their midsection, which is associated with health risks. The fact that the new GLP-1 comes in a pill form offers a convenient option for many women. However, doctors stress that it is also important to select the treatment that is the most effective for you. A new GLP-1 pill called orforglipron (Foundayo) has been shown to help women lose weight, regardless of menopausal status, according to new research. A group of researchers, including senior author Hunter Thomas Hoffman, PharmD, a clinical research scientist affiliated with the drug’s manufacturer, Eli Lilly, analyzed data from two prior trials, ATTAIN-1 and ATTAIN-2, to arrive at this conclusion. These studies reveal that this medication works equally well for women who ha…

≈